Lupin Ltd (LUPIN)
₹2,370.50
Mkt cap
₹1.08L Cr
P/E ratio
19.10
P/B
4.83
Div yield
0.76%
ROE
28.70%
ROCE
29.90%
EPS (TTM)
₹124.11
Book value
₹491
52W range
1,852–2,515
Sector
Healthcare
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−5.74% from high₹2,371
₹1,852+28.01% from low₹2,515
Current
₹2,370.50
Prev close
₹2,371.00
Day
−0.02%
Price performance
1D
−0.02%
1W
−4.36%
1M
+1.15%
3M
+3.24%
6M
+9.33%
1Y
+21.21%
YTD
+12.60%
Financials
FRevenue, profit & margin
P/E ratio
19.1×
LUPIN is 44% below the sector median of 34.0×
LUPIN19.1×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4,430 | 4,814 | 5,039 | 5,197 | 4,961 | 5,600 | 5,673 | 5,768 | 5,667 | 6,268 | 7,048 | 7,168 | 7,475 | |
| Expenses | 3,852 | 3,958 | 4,121 | 4,159 | 3,964 | 4,359 | 4,332 | 4,412 | 4,346 | 4,541 | 4,706 | 4,906 | 4,989 | |
| Operating Profit | 578 | 856 | 918 | 1,038 | 997 | 1,241 | 1,340 | 1,356 | 1,321 | 1,727 | 2,341 | 2,262 | 2,486 | |
| OPM % | 13% | 18% | 18% | 20% | 20% | 22% | 24% | 24% | 23% | 28% | 33% | 32% | 33% | |
| Other Income | 37 | 23 | 40 | 29 | 29 | 68 | 42 | 54 | 57 | 79 | 90 | -312 | 9 | |
| Interest | 93 | 86 | 81 | 74 | 71 | 68 | 71 | 67 | 89 | 92 | 108 | 115 | 120 | |
| Depreciation | 264 | 235 | 248 | 257 | 457 | 248 | 257 | 271 | 393 | 299 | 317 | 313 | 447 | |
| Profit before tax | 258 | 559 | 630 | 736 | 498 | 993 | 1,055 | 1,071 | 896 | 1,416 | 2,007 | 1,522 | 1,928 | |
| Tax % | 6% | 19% | 21% | 16% | 26% | 19% | 19% | 20% | 13% | 14% | 26% | 22% | 24% | |
| Net Profit | 242 | 453 | 495 | 619 | 368 | 806 | 859 | 859 | 782 | 1,221 | 1,485 | 1,181 | 1,469 | |
| EPS in Rs | 5.19 | 9.94 | 10.76 | 13.47 | 7.89 | 17.58 | 18.69 | 18.74 | 16.92 | 26.69 | 32.36 | 25.73 | 31.94 | |
| Raw PDF |
Earnings
EResults dates & reactionsNext results
6 Aug '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.65% · closed higher next day 32 of last 59
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 3 Aug '23◦ | 9 Nov '23 | 7 Feb '24◦ | 7 May '24 | 6 Aug '24◦ | 7 Nov '24◦ | 12 Feb '25 | 15 May '25 | 5 Aug '25◦ | 6 Nov '25◦ | 12 Feb '26◦ | 7 May '26◦ |
| Earnings day | +2.77% | −0.54% | +0.76% | −4.11% | +4.38% | −0.33% | −2.05% | +0.07% | −0.68% | +0.83% | −0.53% | −3.28% |
| +1 day | +4.42% | −2.56% | +1.74% | −3.78% | +7.33% | −1.26% | −0.60% | −0.14% | +4.27% | +1.77% | +0.47% | −8.30% |
| +5 days | +4.01% | −1.22% | +0.68% | −2.53% | +8.54% | −3.59% | −4.32% | −4.96% | +6.72% | +5.10% | +0.38% | −7.48% |
| +15 days | +7.02% | +4.08% | +1.68% | −4.54% | +14.81% | −1.41% | −2.37% | −3.68% | +1.63% | +6.48% | +4.16% | −8.02% |
| +30 days | +10.06% | +5.91% | +0.87% | −6.39% | +13.67% | +2.74% | −1.92% | −6.89% | +10.25% | +8.71% | +2.89% | −4.88% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 18 Per Share | 18.00 | 17 Jul '26 | 17 Jul '26 |
Shareholding
Sas of Jun 202646.85%Promoter
Promoters46.85%
FIIs22.42%0.72
DIIs24.65%0.67
Public6.08%0.05
Government0.00%
Ownership trend
Peers
P7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,723 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.10 | 1,88,697 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,559 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,970 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2026bseFinancial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012bse
Concall transcripts82
TranscriptMay 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024TranscriptAug 2024PPTAug 2024TranscriptMay 2024PPTMay 2024TranscriptFeb 2024PPTFeb 2024TranscriptNov 2023PPTNov 2023
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2d - Lupin schedules Q1 FY27 earnings call on August 7, 2026 at 16:30 IST.Board Meeting Intimation for Considering And Approving The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026. 2d - Board to meet on August 6, 2026, to approve Q1 FY2027 results; trading window closes July 1-August 9.Announcement under Regulation 30 (LODR)-Acquisition 21 Jul - Lupin spun out two oncology programs to Kaveri, receiving 82.2% stake for USD 1.6 million.Announcement under Regulation 30 (LODR)-Newspaper Publication 14 Jul - Copy of Newspaper Advertisement relating to Annual General Meeting and e-voting related information.Announcement under Regulation 30 (LODR)-Press Release / Media Release 14 Jul - Lupin ranked among India’s Top 14 employers in Great Place To Work® India 2026 Nation Builders category.